Radhika Bansal, MBBS, on Early Bone Marrow MRD Evaluation After CAR-T in Multiple Myeloma

Radhika Bansal, MBBS, of the Mayo Clinic, discusses her research on the prognostic value of measurable residual disease (MRD) in bone marrow at month one after chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma. She also discusses the use of imaging to assess MRD status after CAR-T therapy.

Patients who are MRD positive at month one after CAR-T represent a “very high-risk population which could benefit from an early intervention,” Dr. Bansal said.

Dr. Bansal and colleagues presented the results of the study at the 2023 American Society of Clinical Oncology Annual Meeting.